JP2023504166A - 疼痛の治療のためのＫｖ７カリウムチャネル開口薬の使用 - Google Patents

疼痛の治療のためのＫｖ７カリウムチャネル開口薬の使用 Download PDF

Info

Publication number
JP2023504166A
JP2023504166A JP2022532695A JP2022532695A JP2023504166A JP 2023504166 A JP2023504166 A JP 2023504166A JP 2022532695 A JP2022532695 A JP 2022532695A JP 2022532695 A JP2022532695 A JP 2022532695A JP 2023504166 A JP2023504166 A JP 2023504166A
Authority
JP
Japan
Prior art keywords
pain
compound
human
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022532695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504166A5 (enExample
Inventor
ジェイアール ジェームズ フィリップ ジョンソン
グレゴリー エヌ． ビーチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenon Pharmaceuticals Inc
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of JP2023504166A publication Critical patent/JP2023504166A/ja
Publication of JP2023504166A5 publication Critical patent/JP2023504166A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Light Guides In General And Applications Therefor (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
JP2022532695A 2019-12-06 2020-12-04 疼痛の治療のためのＫｖ７カリウムチャネル開口薬の使用 Pending JP2023504166A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962945093P 2019-12-06 2019-12-06
US62/945,093 2019-12-06
US201962948010P 2019-12-13 2019-12-13
US62/948,010 2019-12-13
PCT/US2020/063471 WO2021113757A1 (en) 2019-12-06 2020-12-04 Use of a kv7 potassium channel opener for treating pain

Publications (2)

Publication Number Publication Date
JP2023504166A true JP2023504166A (ja) 2023-02-01
JP2023504166A5 JP2023504166A5 (enExample) 2023-12-12

Family

ID=73856375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022532695A Pending JP2023504166A (ja) 2019-12-06 2020-12-04 疼痛の治療のためのＫｖ７カリウムチャネル開口薬の使用

Country Status (14)

Country Link
EP (1) EP4069211A1 (enExample)
JP (1) JP2023504166A (enExample)
KR (1) KR20220113411A (enExample)
CN (1) CN114786658A (enExample)
AU (1) AU2020397173A1 (enExample)
BR (1) BR112022010733A2 (enExample)
CA (1) CA3159436A1 (enExample)
CL (1) CL2022001477A1 (enExample)
CR (1) CR20220318A (enExample)
IL (1) IL293504A (enExample)
MX (1) MX2022006877A (enExample)
PE (1) PE20221169A1 (enExample)
TW (1) TW202133847A (enExample)
WO (1) WO2021113757A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511220B (zh) 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
CN113698345B (zh) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503447A (ja) * 1999-07-01 2003-01-28 グラクソ グループ リミテッド カリウムチャンネルオープナーの新規用途
JP2007514672A (ja) * 2003-12-17 2007-06-07 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト フルピルチン及びトラマドールの組み合わせ
JP2010501568A (ja) * 2006-08-23 2010-01-21 バレアント ファーマシューティカルズ インターナショナル カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体
JP2013518815A (ja) * 2010-02-01 2013-05-23 バレアント ファーマシューティカルズ インターナショナル カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体
WO2019217924A1 (en) * 2018-05-11 2019-11-14 Xenon Pharmaceuticals Inc. Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US9248122B2 (en) * 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503447A (ja) * 1999-07-01 2003-01-28 グラクソ グループ リミテッド カリウムチャンネルオープナーの新規用途
JP2007514672A (ja) * 2003-12-17 2007-06-07 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト フルピルチン及びトラマドールの組み合わせ
JP2010501568A (ja) * 2006-08-23 2010-01-21 バレアント ファーマシューティカルズ インターナショナル カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体
JP2013518815A (ja) * 2010-02-01 2013-05-23 バレアント ファーマシューティカルズ インターナショナル カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体
WO2019217924A1 (en) * 2018-05-11 2019-11-14 Xenon Pharmaceuticals Inc. Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INT MOL SCI, vol. 20(18):4322, JPN6024043571, 2019, ISSN: 0005583619 *

Also Published As

Publication number Publication date
PE20221169A1 (es) 2022-07-25
WO2021113757A1 (en) 2021-06-10
AU2020397173A1 (en) 2022-06-23
EP4069211A1 (en) 2022-10-12
CN114786658A (zh) 2022-07-22
KR20220113411A (ko) 2022-08-12
TW202133847A (zh) 2021-09-16
CA3159436A1 (en) 2021-06-10
BR112022010733A2 (pt) 2022-08-23
CR20220318A (es) 2022-10-07
MX2022006877A (es) 2022-07-11
CL2022001477A1 (es) 2023-04-28
IL293504A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
US20070099947A1 (en) Methods and compositions for the treatment of brain reward system disorders by combination therapy
US20240342156A1 (en) Methods for treating pain
JP2002541097A (ja) 線維筋痛症及び関連症状の治療におけるフルピルチン
TW200418474A (en) Method of treating post-operative nausea and vomiting
EP1161263A1 (en) Analgesic compositions comprising anti-epileptic compounds and methods of using same
JP2017506244A (ja) ノルイボガイン及び関連化合物を用いた治療方法
EP4069211A1 (en) Use of a kv7 potassium channel opener for treating pain
CA2688542A1 (en) Methods and compositions for administration of oxybutynin
ES2968345T3 (es) Combinaciones de oxicodona y palmitoiletanolamina de N-aciletanolamina para reducir los efectos secundarios asociados a los opioides
NO309965B1 (no) Oralt farmasøytisk antihostepreparat
WO2025064708A1 (en) Compositions comprising oxytocin and methods of treating opioid overdose
US10736874B1 (en) Methods for treating pain associated with sickle cell disease
US20080132531A1 (en) Synergistic combinations of norketamine and opioid analgesics
CA3068036A1 (en) Use to buprenorphine in combination with an opioid to treat pain
EP1734940B1 (en) Combinations of deramciclane and opioids for use as analgesics
CN110279691A (zh) 一种外科术后护理镇痛药物及其用途
HK40080562A (en) Use of a kv7 potassium channel opener for treating pain
AU2004233582B2 (en) Pharmaceutical compositon comprising a cathepsin S inhibitor and an opioid
US20090281194A1 (en) Combinations for treating HIV-associated pain
EP1797883A2 (en) Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
BG109702A (bg) Комбинация на дерамциклан и опиоиди като аналгетици

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241029

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241030

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250430